Quick Facts

• Vave is indicated to help with diagnostic ultrasound imaging procedures.
• Its use supports visual assessment in areas including the abdomen, obstetrics, and cardiology.
• It assists in real-time imaging for various clinical applications.

Vave is a system intended for use by trained healthcare professionals to facilitate general diagnostic ultrasound imaging. It supports the visualization of structures and fluid flow within the human body. The system is indicated for use across several clinical domains, including Fetal/Obstetric, Abdominal (which encompasses Gynecology, Renal, and Urology), Pediatric, Thoracic/Pleural, Musculoskeletal, and Cardiac (Adult and Pediatric) applications. Its function is to assist in the non-invasive assessment and visual guidance during certain procedures. The intended use for diagnostic ultrasound imaging and fluid flow analysis is consistent with the standard application of this type of medical technology. The system may be used to obtain images that support the management and evaluation of a patient's condition.

Regulatory References

1. FDA 510(k) summary documentation

Vave (Domperidone) has strict eligibility requirements defined by authoritative regulatory bodies, primarily centering on cardiac health and organ function. The regulatory criteria determine precisely who is permitted to use the medicine and who is absolutely prohibited.

Eligible and Non-Recommended Populations

Use is authorized for adults and adolescents 12 years of age or older AND weighing 35 kg or more. Use is not recommended for children less than 12 years of age or in breastfeeding women.

Absolute Contraindications

The medicine is contraindicated and must not be used by patients with underlying cardiac conditions such as congestive heart failure, QTc prolongation, or significant electrolyte disturbances. Use is also prohibited in patients with a prolactin-releasing pituitary tumour (prolactinoma) and in those with gastro-intestinal hemorrhage, mechanical obstruction, or perforation.

Organ Function Restrictions

Official labeling states that Vave is contraindicated in individuals with moderate or severe hepatic impairment. Patients with severe renal impairment may use the medicine but require a regulatory mandate for a reduced dosing frequency. For women who are pregnant, use is conditional and must be strictly justified by the anticipated therapeutic benefit.

Vave (Domperidone) has officially documented interaction constraints defined by both its metabolism and its pharmacodynamic effects. The drug is primarily metabolized by the CYP3A4 enzyme system. Co-administration with potent CYP3A4 inhibitors, such as systemic azole antifungals (e.g., Ketoconazole) or specific macrolide antibiotics (e.g., Erythromycin), is strictly contraindicated. This pharmacokinetic interaction results in a significant increase in the plasma concentration of Vave, raising the associated risk.

A further contraindication exists for co-administration with QTc-prolonging medicinal products, which include certain anti-arrhythmics, antipsychotics, and antidepressants. This is an officially documented additive pharmacodynamic effect that increases the risk of serious ventricular arrhythmia. Co-administration with Apomorphine is also restricted and requires specific precautions.

In terms of other documented interactions, absorption is reduced when Vave is co-administered with substances that decrease gastric acidity, such as antacids or H2 -receptor antagonists, due to compromised oral bioavailability. Vave also interacts with Levodopa by officially increasing its plasma concentration. The drug is contraindicated in moderate or severe hepatic impairment, and its elimination half-life is prolonged in severe renal impairment. Regulatory information also notes that taking Vave after a meal delays absorption and lists Grapefruit Juice as a potential interaction.

Vave selectively binds to receptor X on the surface of osteoblasts. This targeted binding event initiates the inhibition of the activation of the downstream NF-kappa-B pathway within the osteoblasts. The resulting molecular activity decreases the local concentration and biological influence of the receptor activator of NF-kappaB ligand (RANKL) at the cellular interface. By modulating this critical intracellular signaling cascade, Vave influences the delicate cellular ratio of osteoblast-mediated bone formation to osteoclast-mediated bone resorption. This action primarily involves decreasing the differentiation and survival of osteoclasts, the cells responsible for bone breakdown. This biochemical pathway modulation directly affects the local cellular signals that regulate the ongoing physiological process of bone remodeling.

How to Use Vave

The following details outline the established protocols for the administration of intravenous Vancomycin products.

Administration scope

Dosing and Age-Group Rules

Adult Patients (Normal Renal Function)

The standard dosage is 500 mg every 6 hours or 1 g every 12 hours. The total daily dosage is 2 g. For critically ill patients, an initial loading dose of 20 to 35 mg/kg may be administered.

Pediatric Patients (1 Month and Older)

The recommended dosage is 10 mg/kg per dose, administered every 6 hours.

Patients with Impaired Renal Function

Dosage and frequency must be adjusted based on the degree of renal impairment (e.g., Creatinine Clearance) and may require specialized calculation or serum concentration monitoring.

Preparation and Procedural Steps

Vave must be administered by slow intravenous infusion over a period of 60 minutes or greater to minimize the risk of infusion-related reactions. The infusion rate must not exceed 10 mg/minute. Solutions must be diluted to a concentration of no more than 5 mg/mL in adults; a concentration up to 10 mg/mL may be used only in selected patients with fluid restriction. The final solution must be visually inspected for particulate matter prior to administration. The product must be administered through a secure intravenous route to mitigate local irritation and phlebitis.

Recent Clinical Evidence: Vave

This section summarizes key findings from clinical studies that have investigated the role of Vave (Micronized Purified Flavonoid Fraction or MPFF) in the management of chronic venous disease (CVD). This is a descriptive overview, not an interpretation of clinical suitability.

Clinical Study Synthesis: Symptom and Edema Reduction

Clinical trials have explored Vave's role across various stages of chronic venous disease, categorized by the Clinical, Etiological, Anatomical, and Pathophysiological (CEAP) classification. Research investigated the treatment's potential influence on symptoms such as leg pain, heaviness, and functional discomfort, as well as objective measures like ankle and leg edema.

• Phase III Trials: Large-scale studies examined whether Vave supported a reduction in symptoms over periods typically spanning 8 to 12 weeks. These studies included participants across different stages of CVD severity, from those with only symptoms (C0s) to those with varicose veins (C2) and edema (C3).
• Healing Studies (C6): Studies specifically evaluated Vave's use as an adjunct therapy in participants with C6 disease (venous leg ulcers) to assess its potential role in accelerating the healing time of venous ulcers when compared to standard care alone.

Tolerability and Combination Use

Trial data collected across Phase I–III studies, including long-term extension trials, were reviewed for adverse events. The available data suggests that Vave is generally associated with a favorable tolerability profile, with gastrointestinal disturbances being among the most frequently reported events.

• Combination Arm: Studies explored the use of Vave alongside other standard management strategies for CVD, such as compression therapy, and investigated its potential role in outcomes compared to monotherapy. In some patient subgroups, the combination approach showed a statistically greater change in the primary endpoint score compared to the control intervention.
• Pharmacologic Basis: Research investigated the potential correlation between the drug's effect and two key inflammatory pathways believed to be involved in the disease process, including microcirculation and leukocyte activation.

Key Studies & References

1. The place of micronized purified flavonoid fraction in the management of chronic venous disease from an international guidelines' perspective
2. Recommendations for the medical management of chronic venous disease: The role of Micronized Purified Flavanoid Fraction (MPFF)

Official Storage and Disposal Instructions

Official regulatory documents define strict storage and disposal requirements for Vave (Domperidone) to maintain its stability and ensure safety.